GMAB · Genmab A/S
$28.52
-0.48 (-1.66%)
At close · Jul 29
Market Cap
$17.51B
Shares
613.94M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$29.00
Open$29.02
Day$28.91–29.38
52W$21.00–35.43
Avg vol 30d1.9M
Short int7.6M · 1.2% float · 3.2d
Short vol34%
Last earningsDec 31, 2025
DataJan 2020–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Moderate
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−0%
below
Price vs 50-day avg
+8%
above
RSI (14)
59
neutral
MACD trend
Negative
52-week position
55%
mid-range
Momentum
relative strength
1-month return
+11%
trailing
6-month return
−13%
trailing
YTD return
−6%
this year
Relative strength
−20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $27 › 200d $29 — 200d above 50d
Institutional flow
Accumulating
75 of 276 funds reported for Jun 30 · net +99.4K sh shares · +11 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.23% of float · ▼ -9.3% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
276 holders — mid 3-yr range
Squeeze score
53
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
34%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
2.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−0%
Neutral
Price vs 50-day avg
+8%
Bullish
RSI (14)
59
Neutral
MACD trend
Negative
Bearish
52-week position
55%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $27 › 200d $29 — 200d above 50d
Institutional flow
Accumulating
75 of 276 funds reported for Jun 30 · net +99.4K sh shares · +11 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.23% of float · ▼ -9.3% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
276 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $21
Now $29 · 55%
52-wk high $35
vs 200-day avg 0%
vs 50-day avg +8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GMAB
this stock
Genmab A/S
|
$17.51B | -5.8% | — | — | 1.2% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GMAB | +3.9% | +11.0% | -12.8% | +5.6% | -5.8% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +4.9% | +11.1% | -20.3% | +6.4% | -14.5% |
Key facts
CIK
1434265
CUSIP
372303206
13F (30d)
92 filings
67 filers
Visit website
Investor relations